Selectivity and potency of cyclin-dependent kinase inhibitors Jayalakshmi SridharNagaraju AkulaNagarajan Pattabiraman OriginalPaper 01 March 2006 Article: 25
Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse F. Ivy CarrollJames L. HowardMichael J. Kuhar OriginalPaper 01 March 2006 Article: 24
Mutant glycosyltransferases assist in the development of a targeted drug delivery system and contrast agents for MRI Pradman K. QasbaBoopathy RamakrishnanElizabeth Boeggeman OriginalPaper 01 March 2006 Article: 23
Commentary: Where and how could biomarkers be used in 2016 M. J. Finley AustinLee Babiss OriginalPaper 01 March 2006 Article: 22
Symbiotic relationship of pharmacogenetics and drugs of abuse Joni L. Rutter OriginalPaper 01 March 2006 Article: 21
Effect of N-1 and N-2 residues on peptide deamidation rate in solution and solid state Bei LiRichard L. SchowenRonald T. Borchardt OriginalPaper 01 March 2006 Article: 20
Noncovalent interactions of drugs with immune receptors may mediate drug-induced hypersensitivity reactions Basil O. GerberWerner J. Pichler OriginalPaper 01 March 2006 Article: 19
Targeting opioid receptor heterodimers: Strategies for screening and drug development Achla GuptaFabien M. DécaillotLakshmi A. Devi OriginalPaper 01 March 2006 Article: 18
Blood pressure as an example of a biomarker that functions as a surrogate Mehul DesaiNorman StockbridgeRobert Temple OriginalPaper 01 March 2006 Article: 17
Molecular recognition of opioid receptor ligands Brian E. KaneBengt SvenssonDavid M. Ferguson OriginalPaper 01 March 2006 Article: 15
Opioid ligands with mixed μ/δ opioid receptor interactions: An emerging approach to novel analgesics Subramaniam Ananthan OriginalPaper 01 March 2006 Article: 14
Activation of G-proteins in brain by endogenous and exogenous cannabinoids Steven R. Childers OriginalPaper 01 March 2006 Article: 13
Cytochrome P450s and other enzymes in drug metabolism and toxicity F. Peter Guengerich OriginalPaper 01 March 2006 Article: 12
Detergent-resistant membrane microdomains in the disposition of the lipid signaling molecule anandamide Matthew J. McFarlandEkaterina A. TerebovaEric L. Barker OriginalPaper 01 March 2006 Article: 11
Safety biomarkers and the clinical development of oncology therapeutics: Considerations for cardiovascular safety and risk management Howard FingertMary Varterasian OriginalPaper 01 March 2006 Article: 10
CNS drug delivery: Opioid peptides and the blood-brain barrier Ken A. WittThomas P. Davis OriginalPaper 01 March 2006 Article: 9
Current status of immunologic approaches to treating tobacco dependence: Vaccines and nicotine-specific antibodies Mark G. LeSageDaniel E. KeylerPaul R. Pentel OriginalPaper 01 March 2006 Article: 8
Role of bioactivation in drug-induced hypersensitivity reactions Joseph P. SandersonDean J. NaisbittB. Kevin Park OriginalPaper 01 March 2006 Article: 7
Mechanisms of drug-induced liver injury Michael P. HoltCynthia Ju OriginalPaper 01 March 2006 Article: 6
The chinchilla microdialysis model for the study of antibiotic distribution to middle ear fluid Belinda W. Y. CheungWei LiuRonald J. Sawchuk OriginalPaper 01 March 2006 Article: 5
Recent progress in the computational prediction of aqueous solubility and absorption Stephen R. JohnsonWeifan Zheng OriginalPaper 01 March 2006 Article: 4
Genetic factors in the predisposition to drug-induced hypersensitivity reactions Munir Pirmohamed OriginalPaper 01 March 2006 Article: 3
The pharmacokinetics of escitalopram in patients with hepatic impairment Johan ArebergJacob Strøyer ChristophersenKarl-Heinz Molz OriginalPaper 01 March 2006 Article: 2
Current industrial practices of assessing permeability and P-glycoprotein interaction Praveen V. BalimaneYong-Hae HanSaeho Chong OriginalPaper 01 March 2006 Article: 1